David E. Blask, Ph.D., M.D.
Department of Structural & Cellular Biology


Research Interests:


Selected Publications:

Hill SM, Cheng C, Yuan L, Mao L, Jockers R, Dauchy B, Frasch T, Blask DE. Declining melatonin levels and MT1 receptor expression in aging rats is associated with enhanced mammary tumor growth and decreased sensitivity to melatonin. Breast Cancer Res Treat. 2010 Jun 12. [Epub ahead of print]

Dauchy, R.T., Blask, D.E., Dauchy, E.M., Davidson, L.K., Tirrell, P.C., Greene, M.W., Tirrell, R.P., Hill, C.R., and Sauer, L.A. Antineoplastic effects of melatonin on a rare malignancy of mesenchymal origin: melatonin receptor-mediated inhibition of signal transduction, linoleic acid metabolism and growth in tissue-isolated human leiomyosarcoma xenografts.  J Pineal Res., 47:32-42, 2009.

Blask, D.E.  Melatonin, sleep disturbance and cancer risk.  Sleep Med. Revs. 13:257-264, 2009 (Invited).

Blask, D.E., Dauchy, R.T.,  Brainard, G.C., and Hanifin, J.P.  Circadian stage-dependent inhibition of human breast cancer metabolism and growth by the nocturnal melatonin signal: consequences of its disruption by light at night in rats and women.  Integ. Cancer
Therap.  8:347-353, 2009 (Invited).

Block, K.I., Hrushesky, W., and Blask, D.  In this issue: circadian disruption and cancer. Integ. Cancer Therap. 8:295-297, 2009 (Invited).

Dauchy RT, Dauchy EM, Davidson LK, Krause JA, Lynch DT, Tirrell PC, Tirrell RP, Sauer LA, Van der Riet P, Blask DE. Inhibition of fatty acid transport and proliferative activity in tissue-isolated human squamous cell cancer xenografts perfused in situ with melatonin or eicosapentaenoic or conjugated linoleic acids. Comp Med. 2007 Aug;57(4):377-82.